Rolls-Royce Submarines has signed an innovative contract with industry experts Assystem, AtkinsRéalis and Frazer-Nash to boost collaboration and gain benefit from the unique nuclear capabilities of each company.
The new Capability Assured…
Category: 6. Business
-
How Israelis should plan investments in a strong market
How Israelis should plan investments in a strong market | The Jerusalem PostJerusalem Post/Business & Innovation/Banking & Finance‘Our prime purpose in this life is to help others. And if you can’t help them, at least don’t hurt them.’…
Continue Reading
-
OECD tries to fix home-office tax traps
OECD tries to fix home-office tax traps | The Jerusalem PostJerusalem Post/Business & Innovation/Banking & FinanceWorking abroad sounds simple, but new OECD guidance still leaves major tax risks for Israelis and foreign firms. Work from home…
Continue Reading
-
New York Times sues Perplexity AI for copying content
New York Times sues Perplexity AI for copying content | The Jerusalem PostJerusalem Post/Business & InnovationThe newspaper also said that Perplexity’s business model relies on scraping and copying content, including paywalled material, to power…
Continue Reading
-
Netflix to buy Warner Bros Discovery’s studios for $72b
Netflix to buy Warner Bros Discovery’s studios for $72b | The Jerusalem PostJerusalem Post/Business & Innovation/All NewsBuying the owner of marquee franchises including “Game of Thrones,” “DC Comics” and “Harry Potter” will further tilt the…
Continue Reading
-
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting – Biogen
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Biogen
Continue Reading
-
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes
Eight abstracts, including four late-breaking abstracts,…
Continue Reading
-
The shifting role of the hospital pharmacist and drug decision-making
Pharmacists are taking on a greater role in patient care while finding ways to contribute more financially and operationally to their health systems. They need the right technology and support to succeed.The shifting role of the…
Continue Reading
-
Healthcare ultimate hedge against AI correction, Kepler Cheuvreux says
Key Points
- Talk of an AI bubble has grown since high-profile investor Michael Burry, known for predicting the housing meltdown ahead of 2008, revealed he is shorting AI players like Nvidia and Palantir.
- Healthcare, meanwhile, is recovering after a…
Continue Reading
-
Real-World Data Support for Lecanemab in Early AD – Medscape
- Real-World Data Support for Lecanemab in Early AD Medscape
- Alzheimer’s drug ‘delays disease for up to eight years’ The Telegraph
- IQWiG Finds No Added Benefit of Leqembi in Early Alzheimer’s NAVLIN DAILY
- Key facts: Biogen’s Alzheimer’s…
Continue Reading